Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
- Conditions
- Aplastic Anemia
- Registration Number
- NCT03906318
- Lead Sponsor
- Incyte Corporation
- Brief Summary
Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of itacitinib in treating aplastic anemia through JAK1 inhibition?
How does itacitinib compare to standard-of-care treatments like immunosuppressive therapy in aplastic anemia?
Are there specific biomarkers that predict response to itacitinib in refractory aplastic anemia cases?
What adverse events are associated with itacitinib use in hematologic disorders and how are they managed?
What are the potential combination therapies involving itacitinib for aplastic anemia treatment?